With this acquisition, Balchem significantly expands its geographic presence in the packaged ethylene oxide market, enabling the company to offer worldwide service and support to its medical device sterilisation customers.
The Chemogas sites in Europe and Asia will form a global network of facilities when combined with Balchem’s sites in the US, making Balchem a global leader in the critical supply of ethylene oxide to the medical device sterilisation industry.
Facilitated by majority shareholder Gilde Equity Management, Chemogas was carved-out of The Linde Group in 2016.
Linde divests Chemogas business
Since the carve-out, growth has been realised on multiple fronts, including the strategic acquisition of Malaysia-based Stereo in 2018 as a stepping stone in the high growth Asia-Pacific region.
“We are now ready to leverage our leading position in Europe and Asia-Pacific and team up with Balchem, to further strengthen our position as a true global reference supplier of packaged specialty gases. We are excited to take on this next step together with them,” said Dirk Battig, CEO of Chemogas-Group.
Ted Harris, Chairman, CEO and President of Balchem, added, “We are very excited to add Chemogas’ team of talented employees and their extensive packaging and supply chain capabilities to Balchem.”
“The combination of our two companies will significantly enhance our ability to service and support our customers on a more global basis.”